We are live on ! Find out more
BLACR

Bellevue Life Sciences Acquisition Corp. Rights
BLACR

Delisted

BLACR was delisted on the 14th of February, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Bellevue Life Sciences Acquisition Corp. Rights in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $681K → $0 (-$681K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 28

Holders
–
Holders Change
-28
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
28
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$100K
2
PC
Periscope Capital
Ontario, Canada
-$65.2K
3
HCI
Harraden Circle Investments
New York
-$58.3K
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$48.7K
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$46.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
– -$100K -836,469 Closed
HCI
2
Harraden Circle Investments
New York
– -$58.3K -524,343 Closed
PC
3
Periscope Capital
Ontario, Canada
– -$65.2K -485,500 Closed
Toronto Dominion Bank
4
Toronto Dominion Bank
Ontario, Canada
– -$48.7K -446,448 Closed
PAMP
5
Polar Asset Management Partners
Ontario, Canada
– -$46.8K -360,000 Closed
ASM
6
ATW SPAC Management
New York
– -$40.4K -311,040 Closed
BFM
7
Boothbay Fund Management
New York
– -$41.8K -311,040 Closed
JP Morgan Chase
8
JP Morgan Chase
New York
– -$36K -300,000 Closed
RCM
9
Rivernorth Capital Management
Florida
– -$28.6K -250,000 Closed
SCM
10
Saba Capital Management
New York
– -$33.6K -250,000 Closed
Walleye Trading
11
Walleye Trading
New York
– -$30.7K -236,430 Closed
CS
12
Clear Street
New York
– -$24.2K -185,932 Closed
HCM
13
Heights Capital Management
California
– -$20.3K -156,176 Closed
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
– -$18K -150,000 Closed
SCM
15
Shaolin Capital Management
Florida
– -$16.3K -125,000 Closed
WAM
16
Wolverine Asset Management
Illinois
– -$15.8K -121,585 Closed
CC
17
Centiva Capital
New York
– -$12K -100,000 Closed
AA
18
AQR Arbitrage
Connecticut
– -$12.8K -98,528 Closed
MTCM
19
Mint Tower Capital Management
Netherlands
– -$10K -75,000 Closed
SIA
20
SkyView Investment Advisors
New Jersey
– -$4K -30,000 Closed
GF
21
Gabelli Funds
New York
– -$3.52K -27,050 Closed
Walleye Capital
22
Walleye Capital
New York
– -$3.42K -26,270 Closed
Citadel Advisors
23
Citadel Advisors
Florida
– -$2.93K -24,383 Closed
GCIA
24
Gabelli & Co Investment Advisers
New York
– -$2.7K -20,800 Closed
FTUS
25
Flow Traders U.S.
New York
– -$2K -15,696 Closed
1
2

BLACR Hedge Fund Activity: Q1 2025 in Review

0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q1 2025, worth a combined $0 — down 100% from $681K a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of BLACR and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Highbridge Capital Management, exiting entirely with an estimated $100K sold.

  • 0 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q1 2025, down from 28 in Q4 2024.
  • Funds reported $0 of Bellevue Life Sciences Acquisition Corp. Rights stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q1 2025 and 28 closed out, a net change of -28 holders.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q1 2025 was Highbridge Capital Management, an estimated $100K sold.

Based on aggregated 13F filings for Q1 2025.